PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Semaglutide and tirzepatide lead to better blood sugar control and weight loss in individuals with type 1 diabetes, US study finds

2024-09-12
(Press-News.org) Semaglutide and tirzepatide treatment lead to significant weight loss and improve blood sugar control in individuals with type 1 diabetes (T1D) who are living with overweight or obesity, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September) has found.

The two relatively new drugs are approved to treat type 2 diabetes and for weight loss. In type 2 diabetes, they help the body produce more insulin when needed. They also reduce the amount of glucose produced by the liver and slow down the digestion of food, all of which help lower blood sugar levels.

And, while they aren’t approved to treat T1D, they are increasingly being prescribed for this purpose, typically in patients who are living with overweight or obesity. 

“Some of the mechanisms through which semaglutide and tirzepatide lower blood sugar in type 2 diabetes are also likely to be relevant in type 1 diabetes,” says study leader Dr Janet Snell-Bergeon, of the University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

“In addition, an increasing number of adults with type 1 diabetes are living with overweight or obesity.  These conditions can lead to insulin resistance, which makes it more difficult for people who have type 1 diabetes to control their blood sugar. Therefore, these drugs may be particularly beneficial for these patients.

“However, there is, as yet, a lack of data, on how effective they are in this group.” 

To address this, Dr Snell-Bergeon and colleagues assessed the effectiveness of the two drugs in T1D patients at a diabetes clinic in the US.

The retrospective study involved reviewing the medical charts of 100 adults with T1D, 50 who were prescribed semaglutide and 50 who were prescribed tirzepatide.  The majority (84% of those prescribed semaglutide and 100% of those prescribed tirzepatide) were living with overweight or obesity.

The participants were matched by computer for age, sex, diabetes duration, body mass index (BMI) and glycated haemoglobin (HbA1c - a measure of how well blood sugar is controlled) with 50 controls – T1D patients not prescribed weight loss medication.

Data were collected at baseline (prior to initiation of weight loss medication) and then for up to one year for each participant.

Mean age (40 vs. 41 years), sex (71 vs. 72 % female), diabetes duration (26 vs. 27 years), BMI (34 vs. 34kg/m2) and HbA1c (7.3% vs 7.3%) did not differ between those receiving the drugs and the controls, respectively.

All of the participants were taking insulin for their diabetes. Insulin pumps were used by 75% of those receiving the drugs and 80% of controls.  The remainder injected insulin multiple times daily.

The results show that those in the semaglutide and tirzepatide groups lost significantly more weight than the controls.

Almost all of those treated with the drugs lost at least 5% of their body weight (77% of semaglutide users, 93% of tirzepatide users), compared to 14% of the controls.

And 47% of those receiving semaglutide and 87% of those receiving tirzepatide lost at least 10% of their body weight.  (None of the controls lost more than 10%.)

The patients taking tirzepatide lost more than twice as much weight as those taking semaglutide.

Those taking semaglutide lost 9.1% of their body weight on average over 12 months, which equates to 19.2lb (8.7kg).  Their BMI decreased by 3kg/m2, on average over 12 months. 

The patients taking tirzepatide lost 21.4% of their body weight, on average after 12 months of use, which equates to 49.4lb (22.4kg). Their BMI decreased by 7.5kg/m2, on average after 12 months.

Dr Snell-Bergeon says: “This amount of weight loss has been seen in other studies of these drugs and is likely to lower the risk of a number of consequences of obesity including heart disease and insulin resistance.”

In contrast, the controls had gained a small amount of weight (0.4%), on average, after 12 months.

Blood sugar, or glycaemic control, improved by a similar amount in those taking the drugs.

There was no difference in weight loss between those who used insulin pumps and those who had injections.

However, the patients in the tirzepatide group were able to reduce the amount of insulin they took.

When their lower body weight was taken into account, by examining daily insulin dose per kg of body weight, insulin dose had decreased by 0.13 units/kg/day after 12 months of treatment – a reduction of 18%.

Dr Snell-Bergeon says: “This is a substantial reduction and is an indication that insulin resistance has improved.”

There were no reported hospitalisations from severe hypoglycaemia or ketosis, complications of diabetes which can occur when diabetes isn’t being adequately controlled, during the study period. 

The researchers conclude that semaglutide and tirzepatide both led to large amounts of weight loss and improved blood sugar control in patients with T1D, even among people using automated insulin delivery systems. 

Dr Snell Bergeon adds: “A growing number of individuals with type 1 diabetes are living with obesity, partly because the intensive insulin therapy that is required to manage blood sugar levels can cause weight gain.

“Semaglutide and tirzepatide can lead to significant weight loss in these patients and improve their blood sugar levels, which could reduce their risk of complications of obesity and diabetes, including heart disease and eye, nerve and kidney problems.

“These drugs could be a valuable addition to insulin in the treatment of type 1 diabetes.  However, larger, prospective trials are now needed to fully evaluate their safety and efficacy in type 1 diabetes patients living with overweight and obesity.”

 

END


ELSE PRESS RELEASES FROM THIS DATE:

Fear of hypoglycaemia remains a major barrier to exercise among adults with type 1 diabetes

2024-09-12
Despite high use of continuous glucose monitoring and insulin pump therapy, fear of hypoglycaemia (low blood sugar) remains a significant barrier to physical activity and exercise for adults with type 1 diabetes (T1D), according to new research to be presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept). However, the findings suggest that if exercise and diabetes management are discussed in the clinic, this fear could be reduced. “Regular exercise can help individuals with diabetes to achieve their blood glucose goals, improve their ...

New technology ‘game changing’ for marathon runners with type 1 diabetes

2024-09-12
A series of case reports to be presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept), describe how a technology giving insulin doses informed by an insulin pump algorithm helped three adults with type 1 diabetes better manage their blood sugars enabling them to lead more active lives, and even run marathons. The AID system contains an advanced hybrid closed loop algorithm that automates the delivery of both basal and correction bolus insulin every 5 minutes based on sensor glucose values. “It is great to see advances in ...

Vitis vinifera and muscadines: Grape breeders seek the best of both grapes

Vitis vinifera and muscadines: Grape breeders seek the best of both grapes
2024-09-12
By John Lovett Arkansas Agricultural Experiment Station FAYETTEVILLE, Ark. — Muscadines may be the folksy American of the grape world, but they have many qualities like disease resistance and unique flavors that are desired in the more popular Vitis vinifera (bunch grapes) species. Likewise, Vitis vinifera — the species that most people eat as table grapes and drink in wine — has many characteristics desirable for muscadines, like thinner skin, a crispier texture and seedlessness. Successfully combining traits from these two species of grapes is a challenge due to differing numbers ...

A new tack for slack: motivate workers

2024-09-12
Workplace communications platforms such as Slack and Microsoft Teams are sometimes accused of reducing productivity by distracting workers with constant messages and the need to respond to them. But new research by Wen Wen, associate professor of information, risk, and operations management (IROM) at Texas McCombs, shows that companies can use them to do the opposite: to motivate workers. How? By praising successful employees in all-staff channels that everyone can see — especially when they can’t see one another face-to-face. “One important challenge faced by many companies is how to motivate remote workers and keep them productive,” ...

UTA harvests first climate-smart soybean crop

UTA harvests first climate-smart soybean crop
2024-09-12
UT Arlington biologists, working with underserved farmers in South Texas, have harvested their first crop of climate-smart soybeans. This harvest is part of a four-and-a-half-year, $5 million project funded by the U.S. Department of Agriculture (USDA) to test whether climate-smart agricultural practices can reduce emissions of greenhouse gases (GHGs) responsible for climate change—including carbon dioxide, methane, and nitrous oxide—while simultaneously increasing crop production. “We ...

JGU hosts annual meeting of the ATLAS Collaborative Research Center

JGU hosts annual meeting of the ATLAS Collaborative Research Center
2024-09-12
The connections between particles and their mass, the composition of the universe out of matter and antimatter and the search for previously unknown particles such as the so-called “dark matter” are the focus of researchers at the research center CERN in Geneva, which is celebrating its 70th birthday this year with events all around the world. In four large-scale experiments, scientists at the Large Hadron Collider (LHC) are getting to the bottom of the secrets of the universe. This particle accelerator offers researchers ...

Med school scientist receives prestigious NSF award for inflammation research

2024-09-12
Associate Professor Justine Tigno-Aranjuez will use a five-year grant of more than $1 million to study how influences on the production of lipid mediators to better understand impacts on inflammation. A College of Medicine researcher has received a prestigious U.S. National Science Foundation CAREER Award to support her research into the cellular causes of inflammation, discoveries that could be pivotal for treating  conditions like Crohn’s disease and arthritis. Justine Tigno-Aranjuez’s lab has been researching lipid mediators — ...

Uptick in drug overdose rates is widely reported especially among young women

2024-09-12
Overdose rates in Colombia involving illegal opioids, hallucinogens, stimulants and sedative psychotropic medication increased greatly during 2018-2021, mainly caused by overdoses in young women, according to a study at Columbia University Mailman School of Public Health. Drug overdoses increased by 356 percent from 8.5 to 40.5 percent per 100,000 individuals from 2010 to 2021. The findings are published in the American Journal of Public Health. The study is the first to describe national ...

Understanding what helps families with teens maintain household vaping bans

2024-09-12
UNIVERSITY PARK, Pa. — In the roughly 20 years since e-cigarettes were introduced in the United States, use among young people has grown substantially. By 2022, more than one in five high school seniors reported they had vaped nicotine in the past month. Household smoking bans — rules against anybody smoking inside a home — are an effective tool for delaying or preventing teen cigarette smoking, according to Jennifer Maggs, professor of human development and family studies at Penn State, and her collaborators, so they examined if the same might hold true for vaping. They assessed how many households with teenage children in the ...

Can AI talk us out of conspiracy theories?

2024-09-12
Have you ever tried to convince a conspiracy theorist that the moon landing wasn’t staged? You likely didn’t succeed, but ChatGPT might have better luck, according to research by MIT Sloan School of Management professor David Rand and American University professor of psychology Thomas Costello, who conducted the research during his postdoctoral position at MIT Sloan. In a new paper “Durably reducing conspiracy beliefs through dialogues with AI” published in Science, the researchers show that large language models can effectively reduce ...

LAST 30 PRESS RELEASES:

SwRI-developed instruments will study potential habitability of Jupiter’s moon Europa

Proposed scoring system may enhance equity in organ transplantation, increase transplant rates and improve patient survival

Survivors of childhood brain cancer are more likely to be held back in school

Updating offshore turbine designs to reflect storms’ complexity is key

Hospital strain during the COVID-19 pandemic and outcomes in older racial and ethnic minority adults

Scientists unveils key role of “selfish DNA” in early human development

Bonobos may be more vulnerable than previously thought, suggests genetics study

Scripps Research scientists discover chemical probes for previously “undruggable” cancer target

Giant Magellan telescope begins primary mirror support system testing

Experimental cancer drug eliminates bone metastases caused by breast cancer in lab models

Political candidates who fight climate change stand to benefit in election

Stand up to Cancer announces new grants supporting pioneering research in six cancer types

Researchers awarded $1.3M to help military Veterans battling Acute Myeloid Leukemia

New hub for high-energy astrophysics — CTAO Science Data Management Centre opens at DESY in Zeuthen

JMIR publications CEO and Executive Editor Gunther Eysenbach achieves #1 ranking as most cited researcher in Medical Informatics for fifth consecutive year

ERC grant for groundbreaking wearable health tech

NIH announces winners of prize competition to improve postpartum maternal health and health equity through innovative diagnostics

APS and SPR honor Dr. Cynthia F. Bearer with the 2025 Mary Ellen Avery Neonatal Research Award

Election delays and voter trust

US air pollution monitoring network has gaps in coverage, say researchers

Continuous monitoring of fatigue in factory workers

Farmer ants’ wearable bacteria

Political polarization and trust

Study uncovers how silkworm moth's odor detection may improve robotics

New study links obesity to elevated hypertension risk among young middle eastern women

How ‘vaccinating’ plants could reduce pesticide use and secure global food supplies

Seven new frog species discovered in Madagascar: sounds like something from Star Trek

New temperatures in two thirds of key tropical forest

Fearful memories of others seen in mouse brain

Rangers lead ground-breaking effort to monitor Uganda's lion population in critical stronghold

[Press-News.org] Semaglutide and tirzepatide lead to better blood sugar control and weight loss in individuals with type 1 diabetes, US study finds